Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

NCT03230318 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma
Combined Hepatocellular and Cholangiocarcinoma

Interventions

DRUG: derazantinib

Sponsor

Basilea Pharmaceutica